Biotech · Private company
Intercept Pharmaceuticals
Track this companyFree. Adds Intercept Pharmaceuticals to your Dealase workspace and tells you when its record changes.
Clinical trials161 recruiting or active
Pipeline programs15From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline15
- FDC tablet (OCA 5 mg + BZF 400 mg SR)Phase 3 · Primary Biliary CholangitisClinicalTrials.gov · fetched Nov 12, 2026
- Obeticholic AcidPhase 3 · Non Alcoholic Steatohepatitis (NASH)ClinicalTrials.gov · fetched Nov 12, 2026
- Obeticholic acid (10 mg to 25 mg)Phase 3 · Compensated CirrhosisClinicalTrials.gov · fetched Nov 12, 2026
- Obeticholic acid (10 mg)Phase 3 · Compensated CirrhosisClinicalTrials.gov · fetched Nov 12, 2026
- Obeticholic Acid (OCA)Phase 3 · Primary Biliary CirrhosisClinicalTrials.gov · fetched Nov 12, 2026
- Bezafibrate 100 mgPhase 2 · Primary Biliary CholangitisClinicalTrials.gov · fetched Nov 12, 2026
- Bezafibrate 200 mgPhase 2 · Primary Biliary CholangitisClinicalTrials.gov · fetched Nov 12, 2026
- INT-747Phase 2 · Liver Cirrhosis, BiliaryClinicalTrials.gov · fetched Nov 12, 2026
- INT-787Phase 2 · Alcohol Associated HepatitisClinicalTrials.gov · fetched Nov 12, 2026
- Obeticholic AcidPhase 2 · Primary Biliary CirrhosisClinicalTrials.gov · fetched Nov 12, 2026
- Obeticholic Acid (OCA)Phase 2 · Liver Cirrhosis, BiliaryClinicalTrials.gov · fetched Nov 12, 2026
- Obeticholic Acid (OCA)Phase 2 · Primary Sclerosing Cholangitis (PSC)ClinicalTrials.gov · fetched Nov 12, 2026
- Obeticholic Acid 5 mgPhase 2 · Primary Biliary CholangitisClinicalTrials.gov · fetched Nov 12, 2026
- Ursodeoxycholic Acid (URSO)Phase 2 · Liver Cirrhosis, BiliaryClinicalTrials.gov · fetched Nov 12, 2026
- Obeticholic Acid 10 MGPrimary Biliary CholangitisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials16
- To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and BezafibratePHASE3 · TERMINATED · started Jul 1, 2024ClinicalTrials.gov NCT06488911 · fetched Nov 12, 2026
- FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) StudyPHASE2 · TERMINATED · started Dec 15, 2022ClinicalTrials.gov NCT05639543 · fetched Nov 12, 2026
- A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC PatientsWITHDRAWN · started Mar 28, 2022ClinicalTrials.gov NCT05293938 · fetched Nov 12, 2026
- Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBCPHASE2 · COMPLETED · started Mar 21, 2022ClinicalTrials.gov NCT05239468 · fetched Nov 12, 2026
- LITMUS Imaging StudyACTIVE_NOT_RECRUITING · started Sep 4, 2019ClinicalTrials.gov NCT05479721 · fetched Nov 12, 2026
- Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic ImpairmentPHASE4 · TERMINATED · started Jun 22, 2018ClinicalTrials.gov NCT03633227 · fetched Nov 12, 2026
- Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisPHASE3 · COMPLETED · started Aug 30, 2017ClinicalTrials.gov NCT03439254 · fetched Nov 12, 2026
- Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) SignalingNA · COMPLETED · started Apr 1, 2016ClinicalTrials.gov NCT02654236 · fetched Nov 12, 2026
- Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid TreatmentPHASE3 · TERMINATED · started Sep 22, 2015ClinicalTrials.gov NCT02548351 · fetched Nov 12, 2026
- Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC PatientsCOMPLETED · started Jun 1, 2015ClinicalTrials.gov NCT05292872 · fetched Nov 12, 2026
- Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)PHASE2 · COMPLETED · started Feb 9, 2015ClinicalTrials.gov NCT02177136 · fetched Nov 12, 2026
- Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary CholangitisPHASE4 · TERMINATED · started Dec 26, 2014ClinicalTrials.gov NCT02308111 · fetched Nov 12, 2026
- Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary CirrhosisPHASE2 · COMPLETED · started Dec 3, 2013ClinicalTrials.gov NCT01865812 · fetched Nov 12, 2026
- Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary CirrhosisPHASE3 · COMPLETED · started Jan 1, 2012ClinicalTrials.gov NCT01473524 · fetched Nov 12, 2026
- Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)PHASE2 · COMPLETED · started Jan 17, 2008ClinicalTrials.gov NCT00570765 · fetched Nov 12, 2026
- Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)PHASE2 · TERMINATED · started Oct 1, 2007ClinicalTrials.gov NCT00550862 · fetched Nov 12, 2026